Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Leigh Turner
Mounting evidence indicates the agency’s Coronavirus Treatment Acceleration Program may be inadequate
Dirk Dusharme @ Quality Digest
Government agencies and consumers fall prey to knockoffs and unapproved vendors
Stanley Chao
Suddenly, everybody and their brother thinks they know how to do business in China
Quality Digest
PPE counterfeits endanger lives. Testing ensures real PPE does its job.
Grant Ramaley
The IAF certification database could help confirm the quality of medical purchases by governments

More Features

FDA Compliance News
Good quality is adding an average of 11 percent to organizations’ revenue growth
Further enhances change management capabilities
Creates adaptive system for managing product development and post-market quality for devices with software elements
VQIP allows for expedited review and importation for approved applicants that demonstrate safe supply chains
An invite from Alcon Laboratories
Intended to harmonize domestic and international requirements
Pharma quality teams will have performance-oriented objectives as well as regulatory compliance goals
Strategic investment positions EtQ to accelerate innovation efforts and growth strategy

More News

FDA Compliance

Manufacturing Standards for Biopharmaceuticals

Conversation with NIST’s Sheng Lin-Gibson and Vijay Srinivasan

Published: Monday, March 2, 2020 - 13:02

Biopharmaceuticals, also known as biological drugs or biologics, are manufactured from living organisms, or contain living organisms that have been genetically engineered to prevent or treat diseases. Biologics are chemically and structurally complex, and often highly heterogeneous; therefore, controlling and maintaining quality remains a challenge. The potential for new therapeutics to cure and treat previously untreatable diseases is enormous, but there is still a long way to go before they can be manufactured at the required scale, with predictive control of quality, and at a lower cost. NIST’s Vijay Srinivasan and Sheng Lin-Gibson discuss their recent paper on some of the challenges and solutions associated with manufacturing these life-saving drugs.

How are the manufacturing processes for biopharmaceuticals different than for other types of drugs? What are some of the technical and operational challenges?

Lin-Gibson
There are lots of challenges because we’re talking about a broad class of therapeutics. We have drugs that look somewhat like small molecules, such as RNA-targeting therapeutics. We have drugs where we have literally gutted a virus to remove the viral genome and replaced it by sequences that, when delivered to patients, can correct the underlying genetic cause of various diseases. We have cells that have been taken from patients, and genetically modified to only recognize and attack cancer cells.

So, the difficulty is that all these drugs are made in different ways. The commonality is that they’re all coming from a living system. Biology is incredibly complex. For one, living systems are inherently dynamic and constantly changing. Second, they tend to be highly heterogeneous. When we talk about cells coming directly from the patient, we have to worry about patient-to-patient variations. Meanwhile, our understanding of the biosciences continues to evolve at an incredibly rapid pace.

That’s really the heart of the manufacturing challenge. How are regulatory agencies going to evaluate the quality and consistency of these products to ensure they’re safe and effective? These are manufacturing and measurement challenges that NIST has been actively working with the industry and other stakeholders to address.

Srinivasan
Coming to this as an engineer with a manufacturing and engineering background, what I found was that the living cell is an amazingly complex and wonderful factory. And what we are trying to do in biopharmaceuticals is to coax this natural factory to produce things that we want, which is very different from how we engineers are used to making things.

We’re changing the manufacturing paradigm, from large centralized factories to smaller, more distributed manufacturing, because practically any licensed hospital could one day manufacture these drugs in-house, on demand. Unlike other types of manufacturing, these cellular factories don’t need enormous amounts of power. Biological reactions involving human cells occur at around 37°C, which you can get from simply plugging a machine into a wall outlet. Now you’re talking about super-small, super-distributed manufacturing.

Think about that, compared to the power and infrastructure needed to run a massive chemical plant. This is a fundamentally different way to think about manufacturing. How do you do manufacturing on demand? How do you manufacture at different scales? How do you control quality? Am I making the same drug in Arizona as I am in Maryland?

These are really interesting challenges that are presented by the new paradigm.

What does smart manufacturing mean in this context?

Srinivasan
It is very difficult to make these drugs using manual processes, so we have to think about how automation and new manufacturing capabilities, biology, physics, and information technology can come together to make these types of products.

Can we envision a future where the therapies are manufactured in a hospital where the patient is being treated?

Hospitals have quality management systems and the control training, so could those evolve to handle distributed biologic manufacturing? What are the additional hurdles that we have to overcome to make that happen?

In manufacturing, we have been talking about mass customization and personalization.

Mass customization and personalization is the same idea as where you don’t have a bunch of shirt sizes and then you go pick one close to what your size is, but rather, you can customize things, manufacturing-wise.

That is where the manufacturing industry is moving for some consumer-related products. Now, biologics can be the extreme case of mass customization and personalization. To me, that’s very exciting.

This is not just a nice to have; you must have this capability. And now manufacturing is moving in that direction.

What is NIST’s role here? How does it fit into our broader initiative?

Lin-Gibson
The overarching NIST role is addressing the measurement challenges. My colleagues and I in the NIST Material Measurement Laboratory are focused on the measurement challenges for cells themselves, and the tissues and gene therapies that can be produced from cell-based manufacturing.

Why? What is the difference between measuring a bottle of cells that are ready to be injected into a patient vs. vitamins that I’m ready to give to a patient? For a molecule like a vitamin, I need to know the chemical structure, which is pretty well established. I need to know the concentration, and there are established methods for determining this.

I have a vial of cells. Those cells are alive. Each cell is likely to be somewhat different. Some of these cells will be therapeutic; some of these cells may cause unintended adverse effects. How do you determine what and how much is in that vial? Is your measurement comparable to one that was made before? What is your traceability chain? They don’t yet have a metrology framework for complex biological systems. We’ve been working on this with stakeholders nationwide but also globally.

As we think about manufacturing, it’s no longer just about the end product; maybe you want to measure the starting materials, the reagents, or intermediates of a manufacturing process. We now also have to think about the supply chain. What does that look like? What are the reagents, and how do you track them? What is the standard for that entire supply chain? How do you document the manufacturing process from start to finish? This is where our work began to converge in a very interesting way with NIST’s Engineering Laboratory.

Srinivasan
That’s another exciting thing about it.

My colleagues and I in the NIST Engineering Laboratory don’t do biological measurements. What we do are lots of the documentary standards that deal with how and in what format you capture the information at various stages in these processes.

In general, documentary standards are extremely important, but even more so here because the Food and Drug Administration (FDA) requires that you gather and keep this information and then you transmit it appropriately along the supply chain.

In my opinion, NIST is uniquely positioned for helping to create documentary standards. We have the Engineering Lab and the Information Technology Lab, both of which contain experts in the engineering and informational aspects of these standards. And then the Material Measurement Lab has expertise in the actual measurement science of these things.

At a recent workshop where many biopharmaceutical industries were represented, one aspect that they talked about was data standards.

And they felt that this is such a high priority that they want to do it within one year, so it’s very exciting that industry sees the importance of standards in order to succeed in this business.

What’s your call to action?

Srinivasan
We have to automate as many of these processes as we can to avoid contamination by viruses or other pathogens, so all aspects of monitoring, control, and automation are extremely important. In addition, information about each link in the chain has to be collected and then exchanged seamlessly among the various players.

What we try to do in our recent paper is explain to this community that there’s this vast area that requires collaboration.

Now, industries are really trying to do this and struggling with it. And that’s why the roadmaps that were presented in this paper were developed to say that these are the important problems that we need to work on. And they very clearly show why engineers such as the robotics and automation people are getting involved in that.

Our goal is to meet industry in this process and use our unique NIST perspective and expertise to help guide them into creating the data standards that are needed.

Lin-Gibson
Some of the output will be standards, many of which can perhaps be adopted from existing standards intended for more established biotechnology sectors. But we need to have conversations about to what extent can we adopt and learn from existing standards and best practices. So that’s where I think a lot of the expertise is required because folks should not be starting from scratch.

On the other hand, when we talk about standards, we are really talking about a lot of different kinds of standards. We also need to address a lot of different measurement challenges before we get too far ahead of ourselves.

I think NIST can really offer a lot to the entire ecosystem.

First published Jan. 28, 2020, on NIST’s Taking Measure blog.

Discuss

About The Authors

Sheng Lin-Gibson’s picture

Sheng Lin-Gibson

Sheng Lin-Gibson is the chief of the Biosystems and Biomaterials Division at the National Institute of Standards and Technology (NIST). She oversees a multidisciplinary research portfolio that includes advanced therapies, precision medicine, synthetic biology and complex microbial systems. She leads and coordinates the development of global standards for emerging biotechnology.

Vijay Srinivasan’s picture

Vijay Srinivasan

Vijay Srinivasan is chief of the Systems Integration Division at the National Institute of Standards and Technology (NIST). The Systems Integration Division focuses on standards and measurement science research for integrating engineering information systems in the manufacturing industry. He joined NIST in 2009 after a 26-year career at IBM.